Revenue
2022
2023
2024
2025
Werewolf Therapeutics, Inc. (HOWL)
Price$0.9223Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $1.9M | $19.9M | $16.4M | — | — |
| Research & development | $44.8M | $56.4M | $41.8M | $53.8M | $35.3M | $16.6M |
| Operating expenses | $60.7M | $75.5M | $60.4M | $72.5M | $50.1M | $22.4M |
| Operating income | −$60.7M | −$73.6M | −$40.5M | −$56.1M | −$50.1M | −$22.4M |
| Operating margin | — | −3,904.19% | −203.09% | −341.78% | — | — |
| EBITDA | −$59.0M | −$71.8M | −$38.7M | −$55.0M | −$49.9M | −$22.3M |
| EBITDA margin | — | −3,807.96% | −194.25% | −335.05% | — | — |
| Net income | −$60.8M | −$70.5M | −$37.4M | −$53.8M | −$50.0M | −$15.0M |
| Net profit margin | — | −3,740.85% | −187.37% | −328.09% | — | — |
| Basic EPSper basic share | -$1.32 | -$1.63 | -$1.05 | -$1.86 | -$10.94 | -$28.08 |
| Diluted EPSper diluted share | -$1.33 | -$1.63 | -$1.05 | -$1.86 | -$10.94 | -$28.08 |
Owners
Reported shareholders
≈9.84%of listed shares
MPM BioImpact LLC / MPM ASSET MANAGEMENT LLC / GADICKE ANSBERT / Oncology Impact Fund (Cayman) Management L.P. / MPM Oncology Innovations Fund GP LLC / MPM ONCOLOGY INNOVATIONS FUND LP / UBS Oncology Impact Fund L.P.4.78M shares · Dec 4, 2025
View holders
| Holder | % owned |
|---|---|
MPM BioImpact LLC / MPM ASSET MANAGEMENT LLC / GADICKE ANSBERT / Oncology Impact Fund (Cayman) Management L.P. / MPM Oncology Innovations Fund GP LLC / MPM ONCOLOGY INNOVATIONS FUND LP / UBS Oncology Impact Fund L.P. | ≈9.84%4.78M shares |
MPM BioVentures 2014 (B), L.P. / MPM BioVentures 2014 GP LLC / MPM BioVentures 2014 LLC / MPM BioVentures 2014, L.P. / MPM Asset Management Investors BV2014 LLC | ≈9.84%4.78M shares |
RA CAPITAL MANAGEMENT, L.P. | 4.91%2.39M shares |
Balyasny Asset Management L.P. | 3.68%1.79M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 2.51%1.22M shares |
RENAISSANCE TECHNOLOGIES LLC | 1.39%674.63K shares |
Lynx1 Capital Management LP | 1.35%657.79K shares |
SPHERA FUNDS MANAGEMENT LTD. | 1.29%626.81K shares |
DC Funds, LP | 1.21%589.1K shares |
Verdad Advisers, LP | 0.72%348.71K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.69%335.82K shares |
BANK OF AMERICA CORP /DE/ | 0.64%311.5K shares |
XTX Topco Ltd | 0.56%271.48K shares |
JANE STREET GROUP, LLC | 0.52%251.84K shares |
UBS Group AG | 0.44%215.84K shares |
VANGUARD FIDUCIARY TRUST CO | 0.32%157.73K shares |
EVNIN LUKE | ≈0.29%143.2K shares |
STATE STREET CORP | 0.25%119.17K shares |
Squarepoint Ops LLC | 0.21%103.24K shares |
BlackRock, Inc. | 0.21%101.57K shares |
Percentages use 48.6M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 29, 2026Form 4 · 10b5-1 | EVNIN LUKEDirector | SellCommon Stock · indirect | 157.1K | $0.30 | $47.1K | 143.2K |
| Jun 17, 2026Form 4 | RA CAPITAL MANAGEMENT, L.P. +3TenPercentOwner | SellCommon Stock · indirect | 27.7K | $0.35 | $9.7K | 303.7K |
| Jun 17, 2026Form 4 | RA CAPITAL MANAGEMENT, L.P. +3TenPercentOwner | SellCommon Stock · indirect | 389.2K | $0.35 | $136.2K | 4.27M |
| Jun 16, 2026Form 4 | RA CAPITAL MANAGEMENT, L.P. +3TenPercentOwner | SellCommon Stock · indirect | 9.9K | $0.37 | $3.7K | 331.4K |
| Jun 16, 2026Form 4 | RA CAPITAL MANAGEMENT, L.P. +3TenPercentOwner | SellCommon Stock · indirect | 139.7K | $0.37 | $51.7K | 4.66M |